The latest price target for Co-Diagnostics (NASDAQ:CODX) was reported by Maxim Group on January 23, 2026. The analyst firm set a price target for $0.00 expecting CODX to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Co-Diagnostics (NASDAQ:CODX) was provided by Maxim Group, and Co-Diagnostics downgraded their hold rating.

There is no last upgrade for Co-Diagnostics

The last downgrade for Co-Diagnostics Inc happened on January 23, 2026 when Maxim Group changed their price target from N/A to N/A for Co-Diagnostics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Co-Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Co-Diagnostics was filed on January 23, 2026 so you should expect the next rating to be made available sometime around January 23, 2027.

While ratings are subjective and will change, the latest Co-Diagnostics (CODX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Co-Diagnostics (CODX) is trading at is $2.63, which is out of the analyst’s predicted range.